EFFECT OF INTRA-ARTERIAL NIMODIPINE ON SUBARACHNOID HEMORRHAGE INJURED BRAIN
Subarachnoid hemorrhage is a pathological condition of the brain, caused by rupture of intracerebral aneurism or arteriovenous malformation, with high morbidity and mortality rate. SAH may conceive permanent brain damage with persistent disability. Vasospasm is the most characteristic pathological state of the vasculature, whose development coincides with onset of bleeding with asymptomatic presentation. The critical extend as a risk factor presents with symptom presentation and indication of brain damage development. Early vasospasm treatment is a priority in prevention of brain ischemia and disability. Existing methods of vasospasm treatment are conservative, endovascular and combined, with simultaneous intraarterial vasodilator application. The aim of this study is to determine whether intraarterial application of Calcium- blocker Nimodipine will generate immediate vasodilation, facilitating endovascular aneurism treatment, resulting in long term resolution of the condition. Fifteen patients with SAH received endovascular treatment in the first 48 hours of hemorrhage onset, with consequent intraarterial Nimodipine application if vasospasm was detected. All patients had ruptured aneurism of anterior circulation. Vessel diameter was measured before and after Nimodipine application. The occurrence and degree of vasodilation, as a difference between both diameters, were considered a confirmation of drug effectiveness. Complete spasm relief occurred in 10 patients, residual vasospasm persisted in 4 patients, no VS relief occurred in 1 patient. Intraarterial Nimodipine application during endovascular brain aneurism treatment effectively relieves vasospasm. Early coiling reduces complication risks and development of post ischemic brain damage.
Key words: Vasospasm, SAH, Nimodipine, Intraarterial, endovascular treatment.
2.Joseph S, Kamble R. Current trends in endovascular management of intracranial aneurysms (including posterior fossa aneurysms and multiple aneurysms). Indian J Radiol Imaging. 2008;18(3):256-63.
3.Biondi A, Ricciardi GK, Puybasset L, Abdennour L, Longo M, Chiras J, Van Effenterre R. Intra-arterial nimodipine for the treatment of symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage: preliminary results. AJNR Am J Neuroradiol. 2004 ;25(6):1067-76.
4.Siasios I, Kapsalaki EZ, Fountas KN. Cerebral vasospasm pharmacological treatment: an update. Neurol Res Int. 2013;2013:571328.
5.Joung KW, Yang KH, Shin WJ, Song MH, Ham K, Jung SC, Lee DH, Suh DC. Anesthetic consideration for neurointerventional procedures. Neurointervention. 2014;9(2):72-7.
6.Bauer AM, Rasmussen PA. Treatment of intracranial vasospasm following subarachnoid hemorrhage. Front Neurol. 2014;5:72.
7.Abd-Elsayed AA, Wehby AS, Farag E. Anesthetic management of patients with intracranial aneurysms. Ochsner J. 2014;14(3):418-25.
8.Chandra A, Li WA, Stone CR, Geng X, Ding Y. The cerebral circulation and cerebrovascular disease I: Anatomy. Brain Circ. 2017;3(2):45-56.
9.Yang W, Huang J. Treatment of middle cerebral artery (MCA) aneurysms: a review of the literature. Chin Neurosurg J 2015;1:1.
10.Kim JH, Park IS, Park KB, Kang DH, Hwang SH. Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2009;46(3):239-44.
11.Francoeur CL, Mayer SA. Management of delayed cerebral ischemia after subarachnoid hemorrhage. Crit Care. 2016;20(1):277.
12.Tykocki T, Kostkiewicz B. Aneurysms of the anterior and posterior cerebral circulation: comparison of the morphometric features. Acta Neurochir (Wien). 2014;156(9):1647-54.
13.Narayan V, Pendharkar H, Devi BI, Bhat DI, Shukla DP. Aggressive management of vasospasm with direct intra-arterial nimodipine therapy. Neurol India. 2018;66(2):416-422.